Nicox Draws Down Last Tranche from Bond Financing Agreement with Kreos Capital to Support Key Development Programs
December 17, 2019
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced it has drawn down the remaining €8 million tranche of debt under its bond financing agreement with Kreos Capital.
Michele Garufi, Chairman and CEO of Nicox, said: “This last tranche of debt from the agreement with Kreos complements our recent equity financing, allowing us to advance key development activities for NCX 470 according to our planned timeline. Phase 2 clinical results for NCX 4251 are imminent, and meetings with the U.S. FDA are planned in early 2020 to discuss the next development steps for NCX 470 and NCX 4251.”
Full details of the bond financing agreement entered into by Nicox with Kreos Capital in January 2019 can be found in the Press Release of January 25th, 2019. Nicox drew down an initial €8 million in January 2019 followed by an additional €4 million in October 2019.